9 Results for "

targeted radiosensitizer

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "targeted radiosensitizer" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-160799
CAS No.: 2412367-83-8
Research Areas:  

Cancer

HA-9104 is a potent and selective inhibitor of cullin-5 neddylation via virtually targeting the V30 pocket of UBE2F. HA-9104 binds to UBE2F, reduces its protein levels, and consequently inhibits cullin-5 neddylation. HA-9104 has potent growth suppression and radiosensitizing activities via targeting the UBE2F-CRL5 axis and causing DNA damage, leading to induction of apoptosis and G2/M arrest in lung and pancreatic cancer cells .
loading...
    loading...
Cat. No.: HY-171135
Research Areas:  

Cancer

Cetuximab MMAE is an antibody-drug conjugate (ADC) targeting EGFR, formed by the random conjugation of the Cetuximab (HY-P9905) antibody and VcMMAE (HY-15575) via reduced interchain cysteines. Cetuximab MMAE binds to EGFR, blocks ligand interactions, inhibits downstream signal transduction, mediates receptor internalization, and delivers MMAE to induce G2/M phase cell cycle arrest, inhibit microtubule polymerization, interfere with mitosis, and exert radiosensitizing effects. Cetuximab MMAE limits the toxicity of free MMAE to EGFR-expressing cells and circumvents EGFR resistance mechanisms. Cetuximab MMAE is applicable to research related to EGFR + tumors .
loading...
    loading...
Cat. No.: HY-P99866
CAS No.: 1314238-96-4
Synonyms: MEHD-7945A; RG 7597

Target:  

EGFR Akt p38 MAPK Apoptosis

Research Areas:  

Cancer

Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody targeting EGFR. Duligotuzumab blocks the binding of ligands to these two receptors, inhibits downstream HER/ErbB, AKT and MAPK signaling pathways, induces antibody-dependent cellular cytotoxicity, reduces the proliferation and migration abilities of cancer cells, promotes apoptosis, exerts radiosensitizing effects, and reverses EGFR resistance in cancer cells. Duligotuzumab can be used in tumor-related research .
loading...
    loading...
Cat. No.: HY-143230
CAS No.: 890056-27-6
Synonyms: OGX-011
Target:  

Apoptosis

Research Areas:  

Cancer

Custirsen (OGX-011) is an antisense oligonucleotide that targets clusterin mRNA. Custirsen induces apoptosis by activating Bax, triggering mitochondrial translocation and cytochrome c release. Custirsen acts as a chemosensitizer, radiosensitizer and hormone sensitizer. Custirsen can be used in research related to prostate cancer, non-small cell lung cancer and metastatic breast cancer .
loading...
    loading...
Cat. No.: HY-176217
Research Areas:  

Cancer

dA-NHbenzylOCF3 is a DNA-targeted radiosensitizer that enhances the sensitivity of tumor cells to X-rays via the dissociative electron attachment (DEA) mechanism. dA-NHbenzylOCF3 shows low cytotoxicity to normal cells and mainly localizes to the cytoplasm and nucleus after entering cells. dA-NHbenzylOCF3 exerts its radiosensitizing effect by inducing cell cycle arrest at the radiation-sensitive G2/M phase. dA-NHbenzylOCF3 can be used for radiosensitization research on malignant tumors such as prostate cancer and breast cancer .
loading...
    loading...
Cat. No.: HY-149556
CAS No.: 3036637-30-3
Target:  

EGFR PI3K

Research Areas:  

Cancer

MTX-241F is a selective small molecule inhibitor targeting EGFR and PI3 kinase family members. MTX-241F is able to penetrate the blood-brain barrier and control tumor growth over the long term. MTX-241F exhibits radiosensitizing activity in patient-derived DIPG neurospheres and may be used in the study of diffuse intrinsic pontine glioma (DIPG) .
loading...
    loading...
Cat. No.: HY-182745
Target:  

VEGFR Apoptosis

Research Areas:  

Cancer

VEGFR-2-IN-85 is a strong VEGFR-2 inhibitor, with an IC50 value of 0.23 μM. VEGFR-2-IN-85 exhibits potent cytotoxic activity against multiple cancer cell lines with minimal toxicity toward normal cells. VEGFR-2-IN-85 also impairs cancer cell migration, likely through modulation of the VEGFR-2/p-Akt pathway. VEGFR-2-IN-85 can induce apoptosis through modulation of Caspase-3, Bax and Bcl-2. VEGFR-2-IN-85 arrests cell cycle at the G2/M phase and has anti-angiogenic activity. VEGFR-2-IN-85 is a targeted radiosensitizer enhancing radiation-induced cytotoxicity. VEGFR-2-IN-85 can be used for research on cancers such as non-small cell lung cancer, breast cancer, and liver cancer .
loading...
    loading...
Cat. No.: HY-15772G
CAS No.: 1421373-65-0
Synonyms: AZD-9291 (GMP); Mereletinib (GMP)
Osimertinib (AZD-9291; Mereletinib) GMP is the GMP level of Osimertinib (HY-15772). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Osimertinib GMP is an inhibitor that selectively targets EGFR T790M and activated EGFR mutants. Osimertinib GMP exerts multiple anti-tumor mechanisms, including radiosensitization, induction of apoptosis and ferroptosis, as well as inhibition of cancer stemness. Osimertinib GMP suppresses EGFR nuclear translocation and downstream survival signaling pathways, significantly reduces cell viability and lipid droplet content, and also exerts synergistic effects with radiotherapy or specific targeted agents to effectively overcome drug resistance and radioresistance. Formulations of Osimertinib GMP modified with liposomes or iRGD enable sustained release, tumor-specific accumulation, and breakthrough of the blood-brain barrier limitation. Osimertinib GMP can be used in research related to radioresistant glioblastoma and non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-15772GL
CAS No.: 1421373-65-0
Synonyms: AZD-9291 (GMP Like); Mereletinib (GMP Like)
Osimertinib (AZD-9291; Mereletinib) GMP Like is the GMP Like level of Osimertinib (HY-15772). GMP Like small molecules works appropriately as an auxiliary reagent for cell research manufacture. Osimertinib GMP Like is an inhibitor that selectively targets EGFR T790M and activated EGFR mutants. Osimertinib GMP Like exerts multiple anti-tumor mechanisms, including radiosensitization, induction of apoptosis and ferroptosis, as well as inhibition of cancer stemness. Osimertinib GMP Like suppresses EGFR nuclear translocation and downstream survival signaling pathways, significantly reduces cell viability and lipid droplet content, and also exerts synergistic effects with radiotherapy or specific targeted agents to effectively overcome drug resistance and radioresistance. Formulations of Osimertinib GMP Like modified with liposomes or iRGD enable sustained release, tumor-specific accumulation, and breakthrough of the blood-brain barrier limitation. Osimertinib GMP Like can be used in research related to radioresistant glioblastoma and non-small cell lung cancer .
loading...
    loading...